Exclusive: Gilead Responds to Health Center Group’s Criticism of its 340B Contract Pharmacy Policy

Gilead told NACHC in a letter yesterday it is concerned about the group's criticism of the company's new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments.

Drug manufacturer Gilead told the National Association of Community Health Centers yesterday that NACHC’s condemnation last month of Gilead’s new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments “seem to represent a misunderstanding of this integrity

Read More »

340B Advocacy Group Expresses Concern About Apparent Unique Feature in J&J’s Contract Pharmacy Policy

RWC-340B says Johnson & Johnson’s new conditions on 340B-purchased drugs when hospitals use contract pharmacies apparently applies also to hospitals’ non-340B-purchased “own use” drugs.

Drug manufacturer Johnson & Johnson’s new conditions on 340B-purchased drugs when hospitals use contract pharmacies apparently apply also to hospitals’ non-340B-purchased “own use” drugs, the group Ryan White Clinics for 340B Access has told its members.

Read More »

News Alert

Exclusive: Leading Health Center Organization Calls Gilead’s New 340B Contract Pharmacy Restrictions “Unconscionable”

NACHC called Gilead's 340B pricing conditions on Vosevi and three of its other hepatitis C drugs "the latest example of corporate greed from a pharmaceutical company."

The National Association of Community Health Centers (NACHC) told drug manufacturer Gilead this morning its new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments are “unconscionable,” “appalling,” “wrongheaded,” and “the latest example of corporate greed from

Read More »

Health Care Provider Groups Slam Gilead’s Conditions on 340B Contract Pharmacy

Harvoni is one of the four hepatitis C drugs that will face restrictions under Gilead's new 340B contract pharmacy policy.

HIV/AIDS clinics and hospitals that participate in the 340B program are condemning drug manufacturer Gilead’s new conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies.

Please Login or Become

Read More »

Non-Hospital 340B Entities Form Group to Fight on Their Own Behalf at National and State Levels

The new non-hospital 340B covered entity group 340B Grantees says its work will include outreach, education, lobbying, and litigation.

Non-hospital 340B covered entities have formed a group called 340B Grantees to fight on their own behalf on legislation, in courts, and perhaps in politics at the federal and state levels.

Please Login or Become a

Read More »

340B Stakeholders Congratulate Egwim on Being Named OPA Director

340B stakeholders congratulated U.S. Public Health Service Lt. Cmdr. Emeka Egwim on his selection as director of the office in HRSA that runs the 340B drug pricing program.

340B provider and drug industry stakeholders joined yesterday in congratulating U.S. Public Health Service Lt. Cmdr. Emeka Egwim on his selection as Director of the U.S. Office of Pharmacy Affairs, the federal agency that runs the 340B drug pricing program.

Read More »

Rural Providers Ask Becerra for Action on 340B Contract Pharmacy and on Hospitals at Risk of Losing 340B Eligibility

The NRHA wants HHS to act against drug companies that deny 340B pricing when covered entities use contract pharmacies and ensure that rural hospitals do not lose their 340B eligibility due to factors related to COVID-19.

The National Rural Health Association (NRHA) asked U.S. Health and Human Services (HHS) Secretary Xavier Becerra this week to act against drug manufacturers that deny 340B pricing when covered entities use contract pharmacies.

Please Login or

Read More »

HHS Secretary Becerra Pledges to Keep Fighting Against 340B Contract Pharmacy Restrictions “Because it’s the Law”

HHS Secretary Xavier Becerra told health centers yesterday that “we’re going to continue to fight” drug manufacturers that restrict 340B pricing when covered entities use contract pharmacies “because it’s the law.”

U.S. Health and Human Services (HHS) Secretary Xavier Becerra said yesterday that “we’re going to continue to fight” drug manufacturers that restrict 340B pricing when covered entities use contract pharmacies “because it’s the law.”

Please Login

Read More »

Hospital Groups Pan GSK’s New 340B Contract Pharmacy Policy, PhRMA Says It Will Continue to Push for Reform

Hospital groups are criticizing GlaxoSmithKline's new 340B contract pharmacy policy. PhRMA says it will keep pushing to change 340B.

America’s Essential Hospitals and 340B Health yesterday denounced GlaxoSmithKline’s (GSK) new restrictions on 340B pricing when hospitals use contract pharmacies. Pharmaceutical Research and Manufacturers of America (PhRMA) said this morning it will keep pushing for “much needed changes” to the

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report